Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug

Blood

Volumn 116, Issue 9, 2010, Pages 1524-1527

  Hu, Jinsong ^a,b   Handisides, Damian R ^c   Van Valckenborgh, Els ^a   De Raeve, Hendrik ^d   Menu, Eline ^a   Vande Broek, Isabelle ^a   Liu, Qian ^c   Sun, Jessica D ^c   Van Camp, Ben ^a   Hart, Charles P ^c   Vanderkerken, Karin ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c Threshold Pharmaceuticals   (United States)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CELL CYCLE PROTEIN; EVOFOSFAMIDE; NITROIMIDAZOLE DERIVATIVE; OXYGEN; PHOSPHORAMIDE MUSTARD; PRODRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL; ANOXIA; APOPTOSIS; BONE MARROW; C57BL MOUSE; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; MALE; METABOLISM; MOUSE; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANOXIA; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; NITROIMIDAZOLES; OXYGEN; PHOSPHORAMIDE MUSTARDS; PRODRUGS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956585456     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-269126     Document Type: Article

References (25)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-2972.
2. Hiruma Y, Honjo T, Jelinek DF, et al. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood. 2009;113(20):4894-4902.
3. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23(1):10-24.
4. Lennon DP, Edmison JM, Caplan AI. Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on in vitro and in vivo osteochondrogenesis. J Cell Physiol. 2001;187(3):345-355.
5. Morrison SJ, Csete M, Groves AK, et al. Culture in reduced levels of oxygen promotes clonogenic sympathoadrenal differentiation by isolated neural crest stem cells. J Neurosci. 2000;20(19):7370-7376.
6. Parmar K, Mauch P, Vergilio JA, et al. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A. 2007;104(13):5431-5436. (Pubitemid 47175697)
7. Brown JM. Tumor hypoxia in cancer therapy. Methods Enzymol. 2007;435:297-321.
8. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res. 2002;62(18):5248-5253.
9. Boyle RG, Travers S. Hypoxia: targeting the tumour. Anticancer Agents Med Chem. 2006;6(4):281-286.
10. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol. 2007;19(6):427-442.
11. Ahn GO, Brown M. Targeting tumors with hypoxia- activated cytotoxins. Front Biosci. 2007;12:3483-3501.
12. Chen Y, Hu L. Design of anticancer prodrugs for reductive activation. Med Res Rev. 2009;29(1):29-64.
13. Duan JX, Jiao H, Kaizerman J, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem. 2008;51(8):2412-2420.
14. Hart CP, Sun J, Liu Q, et al. Efficacy of the hypoxia-activated prodrug TH-302 in a preclinical model of prostate cancer metastasis. Clin Exp Metastasis. 2009;26(7):851-852.
15. Harrison JS, Rameshwar P, Chang V, et al. Oxygen saturation in the bone marrow of healthy volunteers. Blood. 2002;99(1):394.
16. Chow DC, Wenning LA, Miller WM, et al. Modeling pO(2) distributions in the bone marrow hematopoietic compartment: II. Modified Kroghian models. Biophys J. 2001;81(2):685-696.
17. Colla S, Tagliaferri S, Morandi F, et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood. 2007;110(13):4464-4475.
18. Colla S, Storti P, Donofrio G, et al. Hypoxia and hypoxia inducible factor (HIF)-1alpha in multiple myeloma: effect on the pro-angiogenic signature of myeloma cells and the bone marrow microenvironment. Blood. 2008;112(11):596-597.
19. Vanderkerken K, Asosingh K, Croucher P, et al. Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev. 2003;194:196-206. (Pubitemid 36896125)
20. Giuliani N, Colla S, Storti P, et al. Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1alpha in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells. Blood. 2009;114(22):175-176.
21. Konopleva M, Benito J, Shi Y-X, et al. Therapeutic targeting of the hypoxic microenvironment in acute lymphocytic leukemia. Blood. 2009;114(22):805-806.
22. Giatromanolaki A, Koukourakis MI, Pezzella F, et al. Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leuk Lymphoma. 2008;49(11):2181-2186.
23. Hose D, Moreaux J, Meissner T, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114(1):128-143.
24. Kizaka-Kondoh S, Inoue M, Harada H, et al. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 2003;94(12):1021-1028. (Pubitemid 38035514)
25. Arteel GE, Thurman RG, Raleigh JA. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur J Biochem. 1998;253(3):743-750.